A major continental health alert has been triggered across Africa following the confirmation of an imported case of Ebola disease caused by the rare Bundibugyo virus in Abuja, prompting the head of the Africa Centres for Disease Control and Prevention to sharply criticise the international community for decades of vaccine neglect.
The event marks the first time the rare and lethal Bundibugyo strain has entered West Africa during the ongoing epidemic cycle, making Nigeria the fifth African country to record an infection since the broader outbreak emerged in the Democratic Republic of the Congo in May 2026. The wider continental surge has become the geographically fastest-spreading Ebola crisis on record, with the DRC documenting over 9,704 cases and 4,687 deaths across eight provinces, reflecting a case-fatality rate approaching 50 per cent.
According to joint incident declarations from the World Health Organization and the Nigeria Centre for Disease Control and Prevention, the patient is a 42-year-old Ugandan national who arrived at the Nnamdi Azikiwe International Airport in Abuja on 3 October 2026 aboard an international flight routed through Addis Ababa. She experienced initial symptoms four days later on 7 October, presented at a private health facility in the capital on 11 October, and received laboratory confirmation for the Bundibugyo strain on 20 October.
Public health teams have placed 44 primary contacts under isolation and active surveillance, the majority comprising healthcare workers who attended to the patient before strict isolation measures were implemented. Although the patient vacationed in Uganda – which the WHO certified Ebola-free in August – epidemiological tracking by the European Centre for Disease Prevention and Control suggests prior travel through eastern DRC, intensifying regional concerns over undetected community chains across East African transport corridors.
Speaking on Channels Television, Africa CDC Director-General Dr. Jean Kaseya condemned the persistent lack of licensed pharmaceutical defenses, stressing that nineteen years after the Bundibugyo pathogen was first identified in Uganda, no approved vaccine or targeted therapeutic exists. Dr. Kaseya stated that international pharmaceutical partners neglected the virus because it was viewed strictly as an African problem, arguing that an approved vaccine would have been fast-tracked had the threat emerged in Western nations. While the standard Ervebo vaccine protects against the Zaire strain, it lacks validated regulatory efficacy against Bundibugyo, forcing frontline healthcare responders in the DRC to administer it off-label under emergency compassionate use protocols.
In response to the therapeutic gap, the WHO and continental partners launched the TUMAINI clinical trial in Bunia, DRC, to evaluate candidate vaccines engineered specifically for the Bundibugyo virus. Concurrently, the Africa CDC is supporting an Egyptian manufacturer conducting early clinical trials on an indigenous vaccine candidate to establish regional self-reliance.
In Nigeria, the Aviation Ministry and the NCDC have tightened biometric health checks across international airports, with special screening targeted at travelers originating from transit hubs in Nairobi, Addis Ababa, and Kigali.
